Back to School: How biopharma can reboot drug development. Access exclusive analysis here

DG051: Phase IIa data

In a double-blind, placebo-controlled Phase IIa trial DG051 produced significant dose-dependent

Read the full 119 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE